In:
Alzheimer's & Dementia: Translational Research & Clinical Interventions, Wiley, Vol. 3, No. 1 ( 2017-01), p. 74-82
Abstract:
Links between preclinical Alzheimer's disease (AD) and driving difficulty onset would support the use of driving performance as an outcome in primary and secondary prevention trials among older adults (OAs). We examined whether AD biomarkers predicted the onset of driving difficulties among OAs. Methods One hundred four OAs (65+ years) with normal cognition took part in biomarker measurements, a road test, clinical and psychometric batteries, and self‐reported their driving habits. Results Higher values of cerebrospinal fluid (CSF) tau/Aβ 42 and phosphorylated tau (ptau 181 )/Aβ 42 ratios, but not uptake on Pittsburgh compound B amyloid imaging ( P = .12), predicted time to a rating of marginal or fail on the driving test using Cox proportional hazards models. Hazards ratios (95% confidence interval) were 5.75 (1.70–19.53), P = .005 for CSF tau/Aβ 42 ; 6.19 (1.75–21.88), and P = .005 for CSF ptau 181 /Aβ 42 . Discussion Preclinical AD predicted time to receiving a marginal or fail rating on an on‐road driving test. Driving performance shows promise as a functional outcome in AD prevention trials.
Type of Medium:
Online Resource
ISSN:
2352-8737
,
2352-8737
DOI:
10.1016/j.trci.2016.11.006
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2832891-7
Permalink